Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents

Fig. 2

Changes in NT-proBNP concentration from baseline to week 24 in the subgroups stratified by the baseline use of glucose-lowering agents. A The group ratio (canagliflozin vs. glimepiride) of proportional changes from baseline to week 24 in the geometric means of NT-proBNP concentration (* refers to the naïve subgroup). B The proportional changes from baseline to week 24 after canagliflozin treatment in the geometric means of NT-proBNP concentration († refers to the naïve subgroup). DPP-4, dipeptidyl peptidase-4; NT-proBNP, N-terminal pro-brain natriuretic peptide

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840